Article Figures & Data
- Supplementary Methods, Figure Legends, Tables S1 - S4 - Supplementary Table S1. Summary of mutations identified by FoundationOne profiling of the original, pre-neratinib skin metastasis. Supplementary Table S2. Frequency of HER2L869R and HER2T798I mutations. Supplementary Table S3. Sequencing of plasma DNA. Supplementary Table S4. ERBB2 targeted capture.
- Supplementary Figures S1 - S2 - Supplementary Figure S1. HER2L869R and HER3E928G cooperate to drive ERBB signaling output. Supplementary Figure S2. MG132 treatment restores expression of HER2T798I.